Evidence map›Paper›PMID 35793039›Full record

ArticleInvestigational new drugs2022

Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines.

Risa Mia Swain, Lisett Contreras, Armando Varela-Ramirez, Mohammad Hossain, Umashankar Das, Carlos A Valenzuela, Manuel L Penichet, Jonathan R Dimmock, Renato J Aguilera

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Chemical constituents in the rhizome of Curcuma longa and the pharmacological importance of curcumin hybrids.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Recent advances in piperidones as privileged scaffolds for drug discovery and development.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Risa Mia SwainThe Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.
Lisett ContrerasThe Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.
Armando Varela-RamirezThe Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.
Mohammad HossainSchool of Sciences, Indiana University Kokomo, Kokomo, IN, USA.
Umashankar DasDrug Discovery and Development Research Cluster, University of Saskatchewan, Saskatoon, Canada.
Carlos A ValenzuelaThe Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.
Manuel L PenichetDivision of Surgical Oncology, Department of Surgery, Department of Microbiology, Immunology and Molecular Genetics, The Molecular Biology Institute, Jonsson Comprehensive Cancer Center, AIDS Institute, The University of California, Los Angeles (UCLA), California, USA.
Jonathan R DimmockDrug Discovery and Development Research Cluster, University of Saskatchewan, Saskatoon, Canada.
Renato J AguileraThe Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA. raguilera@utep.edu.
The University of Texas at El Paso · USUniversity of Saskatchewan · CAIndiana University Kokomo · USUniversity of California, Los Angeles · US

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI ARSHAD M. KHAN · 2019 to 2026
$35.1M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHLR01CA196266 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARTINEZ-MAZA, OTONIEL, PENICHET, MANUEL L · 2016 to 2020
$3.4M
Characterization of novel compounds with anti-lymphoma activitySC3GM103713 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2013 to 2016
$453k
NCI NIH HHS R01 CA196266NIGMS NIH HHS R25 GM069621NIGMS NIH HHS R25GM069621-18NIGMS NIH HHS SC3 GM103713NIMHD NIH HHS 5U54MD007592NIMHD NIH HHS G12 MD007592NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Cancer remains the second most common cause of death in the US. Due to a recurrent problem with anticancer drug resistance, there is a current need for anticancer drugs with distinct modes of action for combination drug therapy We have tested two novel piperidone compounds, named 2608 (1-dichloroacetyl - 3,5-bis(3,4-difluorobenzylidene)-4-piperidone) and 2610 (1-dichloroacetyl-3,5-bis(3,4-dichlorobenzylidene)-4-piperidone), for their potential cytotoxicity on numerous human cancer cell lines. We found that both compounds were cytotoxic for breast, pancreatic, leukemia, lymphoma, colon, and fibroblast cell lines, with a cytotoxic concentration 50% (CC

Indexed as

Antineoplastic AgentsLymphomaPiperidonesApoptosisCell Line, TumorHumansMaleProstateAntineoplastic AgentsPiperidonesAnticancerApoptosisColorectal CancerCytotoxicityDichloroacetateHematopoietic malignanciesPiperidones

Identifiers

PMID35793039
PMCPMC9896656
OpenAlexW4283832186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.